-
Mashup Score: 0Investigating Novel Immunotherapy Combinations for Advanced Gastric and Esophageal Cancers | Docwire News - 5 day(s) ago
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Source: www.docwirenews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1NAPOLEON-2: Nanoliposomal Irinotecan and Neutropenia in Pancreatic Cancer | Docwire News - 9 day(s) ago
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Source: www.docwirenews.comCategories: General Medicine News, UrologyTweet-
📺 At @ASCO #GU25, Tsuyoshi Shirakawa, MD, PhD, highlighted results of the NAPOLEON-2 trial on nanoliposomal #irinotecan and #fluorouracil/leucovorin in patients with unresectable or recurrent #pancreatic cancer: https://t.co/DT11hsXAQ9 https://t.co/qf7Ku00Fq2
-
-
Mashup Score: 5
At ASCO GI 2025, Boris Pasche, MD, PhD, of Karmanos Cancer Institute gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced HCC.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
🥄 At @ASCO #GI25, Boris Pasche, MD, PhD, of @karmanoscancer gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced hepatocellular carcinoma. 📺 Learn more about how the device works: https://t.co/dbwDBbxgD3 https://t.co/H8PT6VcRZF
-
-
Mashup Score: 1
Dr. Marwan Fakih of City of Hope discusses the phase 2 study of botensilimab and balstilimab for the treatment of refractory microsatellite stable metastatic colorectal cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📺 In a recent interview, Dr. @mgfakih of @cityofhope discusses the phase 2 study of #botensilimab + #balstilimab for the treatment of refractory microsatellite stable metastatic #colorectal cancer with no liver metastases that was presented at ASCO #GI25: https://t.co/ICqb5hLHds https://t.co/97mpSGW3zs
-
-
Mashup Score: 0
Dr. Pant offered insights on the key findings of zanidatamab’s efficacy and safety in HER2-positive BTC.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
📺 We spoke with @DrShubhamPant at @ASCO #GI25 on the latest update from the HERIZON-BTC-302 trial, which highlighted the efficacy of #zanidatamab over standard-of-care therapies in HER2-positive biliary tract cancer: https://t.co/DPdaocfDDr https://t.co/Qjib7OWwto
-
-
Mashup Score: 15Advancing Gastric and Esophageal Cancer Treatment With Biomarker-Driven Strategies | Docwire News - 13 day(s) ago
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Our new roundtable moderated by @YJanjigianMD featured @sonbol_bassam, @doctorC369, @Sam_Cytryn, & Mariela Blum Murphy, MD in a discussion on the upper GI treatment landscape. 📺 Part 1 focuses on advancements in gastric & esophageal cancer therapies: https://t.co/2EPGPl8gJa https://t.co/GPcwIOmmfF
-
-
Mashup Score: 0Tumor Differentiation and Survival Outcomes in Gastric Cancer: The Role of Neoadjuvant Chemotherapy | Docwire News - 14 day(s) ago
As the survival benefits of NAC are inconsistent, a recent study sought to determine how different TRGs impact the survival gains linked to treatment with neoadjuvant chemotherapy.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 As the survival benefits of neoadjuvant #chemotherapy are inconsistent for patients with locally advanced #gastric cancer, a recent study sought to determine how different tumor regression grades impact the survival gains linked to treatment with NAC: https://t.co/PaSuTDPaZH
-
-
Mashup Score: 5BREAKWATER: Encorafenib, Cetuximab, and Chemotherapy for Mutant Metastatic Colorectal Cancer | Docwire News - 16 day(s) ago
Scott Kopetz, MD, PhD, of MD Anderson Cancer Center, discusses the BREAKWATER study on the use of first-line encorafenib plus cetuximab with or without chemotherapy.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
📺 Check out our interview with @skopetz of @MDAndersonNews on the phase 3 BREAKWATER study. 👉 The study analyzed 1L #encorafenib and #cetuximab with FOLFOX against standard-of-care chemotherapy alone for BRAF V600E-mutant metastatic #colorectal cancer: https://t.co/fixAtCvsn4 https://t.co/5JdJxwssUp
-
-
Mashup Score: 17
Dr. Pant offered insights on the key findings of zanidatamab’s efficacy and safety in HER2-positive BTC.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
📺 We spoke with @DrShubhamPant at @ASCO #GI25 on the latest update from the HERIZON-BTC-302 trial, which highlighted the efficacy of #zanidatamab over standard-of-care therapies in HER2-positive biliary tract cancer: https://t.co/DPdaocfDDr https://t.co/Qjib7OWwto
-
-
Mashup Score: 3
At ASCO GI 2025, Jonathan Strosberg, MD, of Moffitt Cancer Center, discusses the use of ICIs in patients with advanced pancreatic NETs who display high TMB and MMR alterations.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📺 At @ASCO #GI25, Dr. Jonathan Strosberg of @MoffittNews discusses the use of immune checkpoint inhibitors in patients with advanced #pancreatic NETs who display high TMB and MMR alterations after treatment with alkylating agents: https://t.co/5vFh37KnbV https://t.co/8Ej8rVTNwD
-
📺 Dr. @Sam_Cytryn of @MSKCancerCenter highlights his trial on a novel immunotherapy combo for refractory #gastroesophageal adenocarcinoma. 🔎 The study evaluates the use of agenT-797, #botensilimab, and #balstilimab, with #ramucirumab and #paclitaxel: https://t.co/kypHZCZE6J https://t.co/dg6ynIAPZ8